Heather N. Allen

Heather N. Allen

Auto-generated profile, based on publicly available information

Heather N. Allen

Department of Anesthesiology and Perioperative Medicine, Center for Neuroscience, Pittsburgh Center for Pain Research, Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in The Journal of Pain
Verified
Journal Article
Closed access
ATAlexis D. Trail
Alexis D. Trail
HAHeather N. Allen
Heather N. Allen
BPBlesson Paul
Blesson Paul
TNTyler S. Nelson
Tyler S. Nelson
JWJames A. Widner
James A. Widner
BKBenedict Kolber
Benedict Kolber

20 April 2026 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
SLSantiago Iván Loya López
Santiago Iván Loya López
KGKimberly Gomez
Kimberly Gomez
APAlessandro Porro
Alessandro Porro
GTGerhard Thiel
Gerhard Thiel
AMAnna Moroni
Anna Moroni
ASAndrea Saponaro
Andrea Saponaro
Hyperpolarization‐activated cyclic nucleotide‐gated 2 (HCN2) channels regulate action potential firing in nociceptors and are critical mediators of neuronal hyperexcitability in response to inflammation and nerve injury. These channels are activated by membrane hyperpolarization and potentiated by direct cAMP binding to their C‐terminal cyclic nucleotide‐binding domain (CNBD). Although a role for cAMP in modulating HCN2 activity and contributing to neuropathic pain has been hypothesized, direct evidence has been lacking. To test this causal link, here we employ TRIP8b nano , comprising a minimal peptide derivative from the brain protein TRIP8b that selectively antagonizes cAMP binding to HCN channels. TRIP8b nano effectively abolished cAMP‐mediated potentiation of HCN2 currents in small‐diameter dorsal root ganglion (DRG) neurons, validating its utility as a functional inhibitor. In a rat model of neuropathic pain, DRG‐targeted expression of TRIP8b nano significantly reduced mechanical and thermal hypersensitivity. These findings provide the first direct evidence that cAMP binding to HCN2 channels drives nociceptor hyperexcitability and neuropathic pain and establishes disruption of this interaction as a promising therapeutic strategy. image Key points: Activation of HCN2 channels is potentiated by cAMP binding to their cyclic nucleotide binding domain (CNBD). TRIP8b nano abolishes cAMP binding to CNBD, thus inhibiting potentiation of HCN2 currents in both HEK 293T cells and rat DRG neurons. TRIP8b nano reduces mechanical and thermal hypersensitivity in a rat model of neuropathic pain. Our findings confirm a direct role of cAMP–HCN2 signalling in neuropathic pain and suggest a new therapeutic target.

18 August 2026 in Pain
Verified
Journal Article
Open access
HAHeather N. Allen
Heather N. Allen
TNTyler S. Nelson
Tyler S. Nelson
NGNitsan Goldstein
Nitsan Goldstein
NGNaomi K. Grabus
Naomi K. Grabus
ABAdam Brandner
Adam Brandner
BTBradley K. Taylor
Bradley K. Taylor
Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.

6 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HAHeather N. Allen
Heather N. Allen
SHSara Hestehave
Sara Hestehave
PDPaz Duran
Paz Duran
TNTyler S. Nelson
Tyler S. Nelson
Rajesh KhannaRajesh Khanna
Rajesh Khanna
Osteoarthritis (OA) represents a significant pain challenge globally, as current treatments are limited and come with substantial and adverse side effects. Voltage-gated calcium channels have proved to be pharmacologically effective targets, with multiple FDA-approved CaV2.2 modulators available for the treatment of pain. Although effective, drugs targeting CaV2.2 are complicated by the same obstacles facing other pain therapeutics-invasive routes of administration, narrow therapeutic windows, side effects, and addiction potential. We have identified a key regulator of CaV2.2 channels, collapsing response mediator protein 2 (CRMP2), that allows us to indirectly regulate CaV2.2 expression and function. We developed a peptidomimetic modulator of CRMP2, CBD3063, that effectively reverses neuropathic and inflammatory pain without negative side effects by reducing membrane expression of CaV2.2. Using a rodent model of OA, we demonstrate the intraperitoneal administration of CBD3063 alleviates both evoked and non-evoked behavioral hallmarks of OA pain. Further, we reveal that CBD3063 reduces OA-induced increased neural activity in the parabrachial nucleus, a key supraspinal site modulating the pain experience. Together, these studies suggest CBD3063 is an effective analgesic for OA pain.

10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
HAHeather N. Allen
Heather N. Allen
ERErick J. Rodríguez-Palma
Erick J. Rodríguez-Palma
TNTyler S. Nelson
Tyler S. Nelson
NGNaomi K. Grabus
Naomi K. Grabus
NDNia A. Dufeal
Nia A. Dufeal
Rajesh KhannaRajesh Khanna
Rajesh Khanna
The parabrachial nucleus (PBN) is a critical hub for pain processing that acts as a switchboard for nociceptive signals, relaying them to forebrain regions that integrate sensory signals with affective aspects of pain. Despite strong evidence for the PBN in pain modulation, the heterogeneity of parabrachial neurons poses a challenge in defining their specific contributions. Here, we identify bombesin receptor subtype 3 ( Brs3 )-expressing neurons as a distinct glutamatergic PBN subpopulation involved in inflammatory heat pain. Using Fos expression analysis and in vivo calcium imaging, we demonstrate that Brs3 neurons exhibit heightened activity in response to noxious and innocuous stimuli following an inflammatory insult. Chemogenetic activation of Brs3 neurons in uninjured mice induces pain-like behaviors, indicating their sufficiency in driving nociceptive responses. While inhibition of Brs3 neurons does not reverse inflammatory pain-induced mechanical allodynia, it effectively reduces heat hypersensitivity, suggesting a specific role in thermal pain processing. Brs3 -expressing neurons encompass multiple previously identified pain-related PBN subpopulations, including those expressing the mu opioid receptor ( Oprm1 ), tachykinin 1 receptor ( Tacr1 ), and neuropeptide Y Y1 receptor ( Npy1r ), positioning Brs3 as a potential unifying marker of heat hypersensitivity circuits. These findings provide new insight into the organization of pain-processing networks in the PBN and highlight Brs3 neurons as a crucial population for inflammatory heat pain.